Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Ron Dior who wrote (993)	5/13/1998 11:04:00 PM
From: MIKE DUBIS	Read Replies (1) \| Respond to of 2135

Ron: I agree whole heartedly with you and for the reasons you stated. Over a 150% increase does not seem justified to me, at least. Mike

To: Ron Dior who wrote (993)	5/14/1998 12:17:00 AM
From: David Winkler	Respond to of 2135

I am glad that you will pay what ever is asked, because you will be paying me!! Is there a risk they won't succeed, of course. BUT they have identified a new approach to the goal and they are using compounds that naturally down regulate the vascularization of tumors. I don't think any of the others have this. MEDX uses chemically modified antibodies to redirect cells to a new target. This is close to using natural mechanisms. Nobody seems to understand the potential for IHP and permeation but you will also pay me what ever I ask for that too and it will be much much bigger than angiostatin and endostatin even if they cure all tumors in everybody!!! Investing is about risk. At 10 ENMD had in my estimation a greater chance to go to say 100 than most other companies and it almost did for about 30 min. It will pass 80 again and next time it will only look back on it from a distance. You may be correct that it will revisit the teens again, but it will only be a visit!! Only invest what you can afford to loose, but if you are correct you will score big.

To: Ron Dior who wrote (993)	5/14/1998 12:59:00 AM
From: Tom Hua	Read Replies (1) \| Respond to of 2135

Ron, this stock reminds me so much of GERN earlier this year. Their "break-through" research/story was featured on all major network TVs, most major newspapers, CNN, CNBC, 20/20 did a segment as well. GERN jumped about 80% following the story, but has since given back all its gains. I fully expect the same with ENMD. Regards, Tom

To: Ron Dior who wrote (993)	5/14/1998 8:39:00 PM
From: MDVistnes	Respond to of 2135

Ron Excellent points. My feelings exactly. I've beem burned several times years ago when I first started buying biotech. Never buy on news. It will be years before product comes out, which gives investors months and months to watch the stock to see where the bottom will be. That's the time to buy if you want this as a long long long term, fairly high risk hold. IMHO

To: Ron Dior who wrote (993)	5/20/1998 10:26:00 PM
From: MoneyMade	Read Replies (2) \| Respond to of 2135

SYMBOL ADVR READ ALL: The next AZT... 98th General Meeting of the American Society for Microbiology May 17-21, 1998, Atlanta, Georgia Controlled Trial of a New Non-Toxic Drug, Reticulose, in the Treatment of Patients with HIV/AIDS Paul Levett University of West Indies School of Clinical Medicine and Research Queen Elizabeth Hospital Barbados 246-427-5586 A-263, Session 252 A trial of this new treatment for HIV/AIDS suggests that it can stimulate the immune system to produce increased CD4 cells without an accompanying rise in HIV viral load.Patients who received Reticulose also gained weight and their clinical condition improved compared to controls.The study was conducted by a team from the University of the West Indies School of Clinical Medicine & Research at the Queen Elizabeth Hospital in Barbados. The team included Dr. Paul N. Levett (clinical microbiologist), Dr. Timothy C. Roach (internal medicine specialist) Dr. Henry S. Fraser (internal medicine specialist), and Ms. Hedy Broome (biostatistician) in collaboration with Dr. Shalom Z. Hirschman, New York-based infectious diseases specialist. Dr. Hirschman is President and CEO of Advanced Viral Research Corp. Yonkers, NY, which manufactures Reticulose and which supported the study.The first presentation of data from this study is to be made at the 98th General Meeting of the American Society for Microbiology, in Atlanta, Georgia, on Thursday, May 21, 1998. A total of 43 patients with HIV-1 infection, who had never received anti-retroviral therapy, were randomized to receive either Reticulose (21 patients) or placebo (22 patients), at a dosage of two 1ml subcutaneous (SC) injections per day for two weeks, followed by 1ml SC per day every other week for a total of 60 days (total 30 days treatment). There were no toxic effects observed in, or reported by, patients receiving Reticulose. In patients with HIV-1 infection, treatment with Reticulose produced an early rise in CD4 counts, with no accompanying rise in plasma HIV RNA levels during this limited period of observation. There were improved clinical outcomes, including weight gain, fewer opportunistic infections and lower mortality in patients who received Reticulose. These findings, and the low cost of Reticulose, could have major implications for alternative treatments for the global patient population with HIV/AIDS. Reticulose is a peptide nucleic acid which acts as an immunomodulator, stimulating the production of cytokines. Other viral infections for which trials of Reticulose are presently underway include hepatitis B and human papillomavirus (HPV) asmusa.org Stock SYMBOL (ADVR)